These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25245424)

  • 1. Chemotherapy use and surgical treatment by receptor subtype in node-negative T1a and T1b female breast cancers, Iowa SEER Registry, 2010 to 2012.
    Schroeder MC; Lynch CF; Abu-Hejleh T; Chrischilles EA; Thomas A
    Clin Breast Cancer; 2015 Feb; 15(1):e27-34. PubMed ID: 25245424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.
    Vaz-Luis I; Ottesen RA; Hughes ME; Mamet R; Burstein HJ; Edge SB; Gonzalez-Angulo AM; Moy B; Rugo HS; Theriault RL; Weeks JC; Winer EP; Lin NU
    J Clin Oncol; 2014 Jul; 32(20):2142-50. PubMed ID: 24888816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
    Fehrenbacher L; Capra AM; Quesenberry CP; Fulton R; Shiraz P; Habel LA
    J Clin Oncol; 2014 Jul; 32(20):2151-8. PubMed ID: 24888815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical Management of Breast Cancer in 2010-2011 SEER Registries by Hormone and HER2 Receptor Status.
    Lizarraga I; Schroeder MC; Weigel RJ; Thomas A
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S566-72. PubMed ID: 25956579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Adjuvant Treatment in Small Node-negative HER2-positive Breast Cancer: Which Subgroup Will Benefit?
    Lin H; Zheng H; Ge C; Wang Q; Tang W; Zhang X; Zhou S; Jin X; Xu X; Du J; Fu J
    Clin Breast Cancer; 2020 Dec; 20(6):503-510. PubMed ID: 32653474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A US Registry-Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer.
    Parsons BM; Uprety D; Smith AL; Borgert AJ; Dietrich LL
    J Natl Compr Canc Netw; 2018 Nov; 16(11):1311-1320. PubMed ID: 30442732
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of Breast Cancer Subtype Defined by Immunohistochemistry Hormone Receptor and HER2 Status on the Incidence of Immediate Postmastectomy Reconstruction.
    Wu W; Cheng S; Deng H; Wu J; Mao K; Cao M
    Medicine (Baltimore); 2016 Jan; 95(3):e2547. PubMed ID: 26817902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
    Colleoni M; Cole BF; Viale G; Regan MM; Price KN; Maiorano E; Mastropasqua MG; Crivellari D; Gelber RD; Goldhirsch A; Coates AS; Gusterson BA
    J Clin Oncol; 2010 Jun; 28(18):2966-73. PubMed ID: 20458051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
    Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
    Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer?
    Wang C; Zhou Y; Zhu H; Huang W; Chen Z; Mao F; Lin Y; Zhang X; Shen S; Zhong Y; Li Y; Sun Q
    Cancer Med; 2018 Nov; 7(11):5420-5430. PubMed ID: 30277006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy.
    Ho AY; Gupta G; King TA; Perez CA; Patil SM; Rogers KH; Wen YH; Brogi E; Morrow M; Hudis CA; Traina T; McCormick B; Powell SN; Robson ME
    Cancer; 2012 Oct; 118(20):4944-52. PubMed ID: 22392492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer.
    Ogiya R; Sagara Y; Niikura N; Freedman RA
    Clin Breast Cancer; 2019 Jun; 19(3):200-207.e1. PubMed ID: 30795886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
    Park S; Han Y; Liu Y; Toriola AT; Peterson LL; Colditz GA; Kim SI; Cho YU; Park BW; Park Y
    Breast Cancer Res; 2019 Oct; 21(1):110. PubMed ID: 31619259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
    Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
    J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
    Alramadhan M; Ryu JM; Rayzah M; Nam SJ; Kim SW; Yu J; Lee SK; Bae SY; Park S; Paik HJ; Lee JE
    Breast; 2016 Dec; 30():111-117. PubMed ID: 27697675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort.
    Shen K; Yao L; Zhu J; Gu X; Wang J; Qian W; Zheng Z; Fu D; Wu S
    BMC Cancer; 2022 Aug; 22(1):863. PubMed ID: 35941565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast-Conserving Therapy Versus Mastectomy in Young Breast Cancer Patients Concerning Molecular Subtypes: A SEER Population-Based Study.
    Yu P; Tang H; Zou Y; Liu P; Tian W; Zhang K; Xie X; Ye F
    Cancer Control; 2020; 27(1):1073274820976667. PubMed ID: 33356518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Neoadjuvant Chemotherapy on Patients With T1N0M0 Triple-Negative and HER-2 Positive Breast Cancer: A Retrospective Analysis Based on the SEER Database.
    Cheng H; Dai Q; Liu G; Tong X; Wang Y
    Clin Breast Cancer; 2024 Oct; 24(7):e593-e599. PubMed ID: 38890023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.